Defining the transcriptional profiles of substantia nigra pars compacta and ventral tegmental area dopamine neurons may reveal mechanisms underlying their differential vulnerabilities in Parkinson's disease. Existing studies display extensive variability due to small sample sizes, resulting in troublingly few reproducible subtype-specific markers. We combine spatial transcriptomics (LCM-seq) on human tissue with an iterative, random pooling algorithm, that reveal novel genes which robustly identify dopamine neuron subtypes across species.
Midbrain dopamine neurons are divided into two major subpopulations, the substantia nigra pars compacta (SNc) and the ventral tegmental area (VTA). SNc dopamine neurons project to the dorsolateral striatum and are severely affected in Parkinson's Disease (PD). VTA dopamine neurons project to cortical and mesolimbic areas and are more resilient to degeneration. These subtypes have been extensively investigated in numerous models towards the goal of identifying molecular mechanisms that can prevent degeneration or to model disease. As SNc dopamine neurons represent the ideal cell type for transplantation in PD 1-3 , a targeted and thorough transcriptional profiling will serve as a foundation for their in vitro derivation. When we revisit previous publications addressing the identity of VTA and SNc midbrain dopamine neurons in mouse and rat 4-8 , we find that a surprisingly low fraction of differentially expressed genes (DEGs) are common to all studies ( Supplementary Tables 1 and 3 and Supplementary Fig. 1a,b ). Crosscomparison of these genes with our previously published human dataset 9 ( Supplementary Tables  1 and 3) , identify overlap only of SOX6 and CALB1 across SNc and VTA gene lists, respectively ( Supplementary Fig. 1c ). These discrepancies highlight the urgent need for a more thorough investigation into VTA and SNc identity across different species, with particular focus on the adult human brain.
Previously, we have applied the highly sensitive spatial transcriptomic method LCM-seq in post mortem tissues from three female human subjects 9 . We have now expanded our analysis of dopamine neurons individually isolated from SNc and VTA, to include an additional 18 adult male human subjects ( Supplementary Fig. 2a -h, Supplementary Table 2 ). DESEq2 analysis, considering the latter 18 male subjects, identified 74 differentially expressed genes (DEGs) ( Supplementary Table 4 ), which hierarchically resolved SNc from VTA neurons (Fig. 1a) .
Reassuringly, these genes also distinguished SNc and VTA samples from our previous study of three female subjects 9 (Fig. 1b ). However, given the little overlap with our previously published DEG list we compared the resolutive power of the 74 DEGs with that of the 100 DEGs identified using a small cohort of only three female subjects (published in Nichterwitz et al.) ( Supplementary Fig. 2i , Supplementary Table 5 ). Notably, the 100 previously identified DEGs fully resolved the SNc and VTA of the small Nichterwitz et al. cohort, but were not as robust in separating the 18 male subjects ( Supplementary Fig. 2i-j) . Moreover, when DEGs from the two datasets were compared (Fig. 1c ), only 7 and 21 genes overlapped in SNc and VTA gene lists, respectively. This discrepancy highlights the difficulty in analyzing transcriptome data from small cohorts of human subjects that were likely confounded by individual variations. Consequently, subsets of lineage-specific markers may fall into significance depending on the size of different cohorts, resulting in potentially few commonly shared genes across the groups.
To address this problem, we designed a random pooling algorithm ( Fig. 1d , see methods), available at https://github.com/shanglicheng/RandomPooling, that iteratively samples an increasing proportion of a cohort of subjects, while performing DESeq2 analysis at each iteration. Upon completion, genes are ranked according to the cumulative frequency that they were scored as differentially expressed, as a function of sample size. To reduce the individual variability, we selected 12 subjects from our cohort from which both SNc and VTA samples were available. Application of this random pooling strategy to these 24 samples yielded frequency ranks of DEGs for SNc and VTA ( Supplementary Fig. 2k -l, Supplementary Table 6 ) that included many existing human and/or rodent SNc and VTA markers [4] [5] [6] [7] [8] [9] [10] [11] [12] (Supplementary Table 3 ). We then designated genes within the top 30% of the most frequent genes' score, as "stable DEGs". This resulted in eight genes for the SNc (Fig. 1e , Supplementary Table 6 ) and 25 genes for the VTA (Fig. 1f , Supplementary Table 6 ). Importantly, many of the stable genes (labeled in red* for SNc and blue* for VTA) were among the aforementioned overlapping DEGs (Fig. 1c) . Notably, these genes became stably differentially expressed only as at least eight subjects were included in the random pooling strategy ( Fig. 1e,f ), suggesting this to be roughly the minimal cohort size required to distinguish these two closely related subpopulations. The expression of SNc stable genes was validated in two independent human microarray datasets 10,12 (which lacked VTA samples for comparison) ( Supplementary Fig. 2m ). Finally, these 33 stable genes faithfully classified all 18 male subjects from our current dataset together with three female subjects investigated previously 9 (Fig. 1g ). Moreover, these samples represent the largest human dataset profiling of SNc and VTA dopamine neurons to date.
To investigate cross-species similarities, we applied our random pooling algorithm to an adult mouse single-cell dataset 8 ( Supplementary Fig. 3a -c). Single cells from all postnatal ages were initially assessed for expression of known dopamine neuron markers ( Supplementary Fig. 3a ,b) prior to iterative random pooling and differential gene expression analysis ( Supplementary Fig.  3c ). We identified 35 stable SNc genes and 53 stable VTA genes ( Fig. 2a,b , Supplementary  Table 7 ). These 88 genes effectively classified all single cells into their correct subtype ( Supplementary Fig. 3d ). Several stable genes for SNc and VTA were novel, while others were previously described [4] [5] [6] [7] [8] 11 ( Supplementary Fig. 3e ,f, red labels). Some markers previously reported as differentially expressed [4] [5] [6] [7] [8] 11 ranked just below our 30% frequency cutoff and were thus not designated as stable ( Fig. 3e ,f, black labels).
We next investigated the overlap between our human and mouse stable genes ( Fig. 2c ). Two genes, ZCCHC12 and CDH13, were common to human and mouse VTA. A third gene SERPINE2, was expressed in human VTA, while it's mouse homolog Serpine2, was expressed in the mouse SNc. To investigate the predictive power of these three common genes, we established a workflow whereby samples would be hierarchically clustered, and then scored for accuracy, according to the percentage of samples that were correctly classified, such that 100% reflects perfect accuracy, and 50% reflects a random outcome (see methods). Further, this was performed with either the full list of stable genes, or excluding the three common genes, on either human and mouse samples ( Fig. 2d -l). As expected, when using a complete stable gene list to resolve samples within that same species, negligible reduction in the accuracy was observed after removal of the three common genes in either mouse ( Fig. 2d ,e) or human ( Fig. 2i,j) . Surprisingly, despite their poor overlap, both species' stable genes could moderately separate the other species (Fig. 2f,k) . However, subsequent exclusion of the three common genes led to a dramatic reduction in accuracy ( Fig. 2g ,l). This was most pronounced when mouse-specific stable genes (i.e. excluding Zcchc12, Cdh13 and Serpin2) were used to resolve human samples, resulting in a significant decreased accuracy of 56.76%, (Fig. 2l ), versus 72.02% for humanspecific stable genes (i.e. excluding ZCCHC12, CDH13 and SERPIN2) applied to mouse samples ( Fig. 2g ). These results highlight the significant predictive power of these three common genes, which alone could accurately classify SNc or VTA samples in either species (Fig. 2h ,m). The low fraction of common genes may be due to non-overlapping stable genes (43 for SNc, and 73 for VTA, Fig. 2c ) falling outside the specified 30% frequency threshold. Thus, using this same exclusion paradigm, we calculated the accuracy to resolve cross-species SNc and VTA samples upon random exclusion of any three stable genes (see methods, Fig. 3a and Supplementary Fig. 4a ). Briefly, scores were determined for each stable gene by calculating the mean decrease in accuracy following exclusion of the given stable gene together with any two other stable genes. Previous exclusion of CDH13, ZCCHC12 and SERPINE2 from the human stable list reduced the accuracy in classifying mouse samples from 84.36% to 72.02% ( Fig. 2f,g) , and in this new workflow SERPINE2 accordingly occupied the top rank, while ZCCHC12 and CDH13 occupied ranks 7 and 24 respectively ( Fig. 3a) . Given that previous exclusion of Cdh13, Zcchc12 and Serpine2 from the mouse stable list drastically reduced the accuracy in resolving human samples (from 86.41% to 56.76%, Fig. 2k ,l), it was not unexpected that these three common genes occupied the very top ranks (1, 4 and 6 respectively) ( Supplementary Fig. 4a ). These genes also displayed definitive expression patterns in adult mouse (Figure 3b , P56, Allen Institute for Brain Science, available from http://developingmouse.brain-map.org). Exclusion of other human stable genes could also impair classification accuracy of mouse samples, including, FXYD6, GSGL1, ATP2A3, NECAB1, and LY6H ( Fig. 3a,c ). Using immunohistochemistry in human post mortem tissue ( Supplementary Table 8 ), we confirmed differential gene expression at the protein level for the human stable genes ATP2A3 and CRYM ( Fig. 3d ).
Moreover, further investigation of the mouse stable lists revealed that Calb1, an established VTA marker in both mouse 5,7,8 ( Fig. 3c ) and human 9 (Fig. 3d ), strongly contributed to the separation of human samples ( Supplementary Fig. 4a ). In line with this, its' rank on the human VTA list was close to the 30% frequency threshold ( Supplementary Fig. 2l ). Other mouse stable genes, whose exclusion mildly impaired classification of human samples, also fell just outside the 30% frequency threshold for human stable genes (e.g. Slc1a2, Maoa, Tppp3, Lix1, Adrbk2) ( Supplementary Fig. 2k,l) . In situ analysis of these genes in adult mouse was consistent with their differential enrichment in human samples ( Supplementary Fig. 4b ,c, green labels). Finally, many novel mouse stable genes that had little impact on classification of human samples, also displayed expression patterns in line with their membership to either the SNc or VTA mouse stable gene lists ( Supplementary Fig4 . b,c, black labels).
In summary, we have used spatial transcriptomics with a novel random pooling algorithm that enabled us to derive robust and unique lists of SNc and VTA markers for both human and mouse. Interestingly, we find that only three genes are equally and strongly predictive across the two species. This highlights the vital need to appreciate the human marker profiles of these clinically relevant and highly similar dopaminergic sub-lineages. Such profiles will be invaluable for in vitro modeling of selective vulnerability, as well as for the derivation of authentic SNc neurons for use in cell transplantation strategies targeting Parkinson's disease.
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Ethics statement
We have ethical approval to work with human post-mortem samples ( Supplementary Tables 2  and 9 ) from the regional ethical review board of Stockholm, Sweden (EPN 2012/111-31/1). Fresh frozen tissue or paraffin embedded samples were obtained through the National Disease Research Interchange (NDRI) or the Netherlands Brain Bank (NBB) with the written informed consent from the donors or the next of kin. The work with human tissues was carried out according to the Code of Ethics of the World Medical Association (Declaration of Helsinki).
Tissue sectioning
Sample preparation prior LCM-seq was carried out as follows. Frozen midbrain tissues obtained from the brain banks were attached to chucks using pre-cooled OCT embedding medium (Histolab). 10µm-thick coronal sections were acquired in a cryostat at -20 °C and placed onto precooled-PEN membrane glass slides (Zeiss). The slides with sections were kept at -20 °C during the sectioning and subsequently stored at -80 °C until further processed.
For immunohistochemistry, tissues from NDRI were fixed in PFA, cryoprotected by sequential gradients of sucrose (2%, 10%, 20% and 30%) and sectioned at 40µm on a freezing microtome. Tissues embedded in paraffin (NBB) were sectioned at 10µm on a sliding microtome. All tissue was subjected to antigen retrieval (0.01 M citric acid buffer, pH 6.0) for 20 min at 95 °C and treated to inactivate endogenous peroxidases (3% H 2 O 2 , 50% methanol in PBS) prior to staining.
LCM-seq
The laser capture procedure followed by sequencing library preparation was carried out as described 9,13 .
Read mapping, gene expression quantification and quality control
Samples were sequenced using an Illumina HiSeq2000 or HiSeq2500 platform (reads of 43 or 50 bp in length respectively). The uniquely mapped reads were obtained by mapping to the human reference genome hg38/GRCh38 using STAR with default settings. The reads per kilobase of transcript per million mapped reads (RPKM) were estimated using ¨rpkmforgenes¨1 4 .
As part of the quality control we verified that samples had over 4.7±2.0 million reads and 10.5±1.1 kilo genes expressed with RPKM>1. Correlation across the samples was considered above 0.7. Additionally, we confirmed the expression on known midbrain dopamine neuron markers and the purity of each sample (see Supplementary Fig. 2h ).
Differentially expressed analyses
Differentially expressed genes were identified using the R package ¨DESeq2¨ (current version: 1.16.1) where the cutoff for significance was an adjusted P value of 0.05. Identified DEGs (from different analysis and summarized below) are shown in Supplementary Tables 3 to 7. 
Supplementary
Random pooling algorithm
To counteract the variability among human subjects and identify the most reliable DEGs between SNc and VTA neurons across datasets we developed a random pooling algorithm ( Fig.  1d and Supplementary Fig. 3c ). The stable genes output of this analysis is correlated with the sample size and give an unbiased estimation of the number of individuals required to consistently distinguish these closely related subpopulations. Importantly this computational tool can be used for the comparison of any other two groups (https://github.com/shanglicheng/RandomPooling). In details: 1) Define ¨N¨ and ¨M¨ as the number of samples in Group 1 and Group 2, respectively. 2) Define ¨n¨ and ¨m¨ as the number of randomly selected samples from Group1 and Group2, where n∈{3, 4, 5, …, N} and m∈{3, 4, 5, …, M}. 3) Pool ¨n¨ and ¨m¨ samples (temporary considered a ¨new data set¨) and calculate DEG. 4) Repeat steps 2) and 3) for ¨j¨ times (set to 1000 times in this study). 5) For every round, save the full list of DEGs, compute and rank their frequency. 6) Set a threshold (30% ratio in this study) to consider DEGs with higher frequency as stable genes. Reliable genes appear when frequencies are above: Total times of random pooling x ratio (300 in this study). A stringent, but fair ratio can be defined by comparing the percentage of identified stable genes overlapping with the top 10%, 20%, 30% DEGs.
Random pooling applied to human samples
To reliable identify DEGs between human SNc and VTA samples, while minimizing subject variability, we selected 12 individuals (66% of the dataset) where both neuronal groups were available and sequenced. Hence, the number of randomly selected samples (¨n¨ and ¨m¨ from ¨i¨ individuals) was from three to 11 and the algorithm repeated 1000 times (Fig. 1d ).
Random pooling applied to mouse single cells
For this adult mouse dataset (La Mano et. al, 2016) we defined the groups SNc (N=73 cells) and VTA (M=170 cells comprising VTA1, VTA2, VTA3 and VTA4). To compensate the unbalance in cell number and adjust dataset representation compared to the human analysis (66%, 12 out of 18 individuals), we first randomly collected a subset of 73 VTA cells, pairing both SNc and VTA. Similarly, the number of randomly selected samples (¨n¨ and ¨m¨ from ¨i¨ cells) was from 20 to 70 and the algorithm repeated again 1000 times ( Supplementary Fig. 3c ).
Accuracy calculation to distinguish SNc and VTA samples
To measure the power of stable genes in resolving SNc and VTA samples we calculated the accuracy. This is a quantitative parameter associated with correct group prediction using hierarchical clustering based on the first two dimensions (PC1 and PC2) of the PCA visualizing a given dataset. As we have two predicted groups (SNc and VTA), the minimum value for the accuracy is 50%. In details: 1) Define ¨N¨ and ¨M¨ as the total number of samples in Group 1 and Group 2, respectively. 2) Define ¨n¨ and ¨m¨ as the number of correctly predicted samples for Group1 and Group2, respectively.
3) Accuracy, expressed as percent, is calculated according to the formula: Accuracy (%)= ((¨n¨+¨m¨)/(¨N¨+¨M¨)) * 100
We calculated the accuracy for six different conditions (stable gene sets) as follows: a) Mouse stable genes applied to mouse (Fig. 2d) or human (Fig. 2k) samples. b) Mouse stable genes excluding (Zcchc12, Cdh13, Serpine2) applied to mouse ( Fig. 2e) or human (Fig. 2l) samples. c) Human stable genes applied to mouse (Fig. 2f ) or human (Fig. 2i ) samples. d) Human stable genes excluding (ZCCHC12, CDH13, SERPINE2) applied to mouse (Fig.  2g ) or human (Fig. 2j) samples. e) Mouse stable genes excluding three random markers applied to human samples ( Supplementary Fig. 4a ). f) Human stable genes excluding three random markers applied to mouse samples (Fig. 3a) .
To identify additional (but not common) stable genes from mouse or human with resolving power to the other species, we performed the above analysis e) and f). Here we ranked the mean accuracy for a given stable gene upon random exclusion with any two others.
Immunohistochemistry of human tissues
We selected two human stable genes (ATP2A3 and CRYM) in addition to CALB1 to confirm their differential expression at the protein level with a peroxidase-based system 15 . Tissue sections in glass slides were blocked in PBS with 10% donkey serum and incubated with primary antibodies in 0.1% Triton X-100 in PBS with 10% donkey serum. Stainings against ATP2A3 (HPA007180, rabbit polyclonal, Sigma-Aldrich) or CRYM (HPA019086, rabbit polyclonal, Sigma-Aldrich) were carried out overnight at 4°C using 1 in 25 antibody dilution whereas CALB1 (1 in 300 dilution, mouse monoclonal, Swant) was detected after 48 h incubation at 4°C. Incubation with biotinylated secondary antibodies (1:300; Jackson Laboratories) were carried out for 3 h, followed by 1 h incubation in streptavidin-biotin complex (Vectastain ABC kit Elite, Vector Laboratories, Burlingame, CA, USA). Visualization was achieved after 10min incubation with 3,3 ' -diaminobenzidine solution (DAB, Vector Laboratories). Negative controls were performed for all stainings by omitting primary antibody. Cell nuclei were counterstained using Myers hematoxylin (Histolab) and tissue was dehydrated by sequential steps in increasing ethanol concentration and xylene prior preservation using coverslips with Mountex (Histolab).
Intensity measurements for quantification
For every staining, we imaged 5-7 random fields within the SNc and VTA regions. On average 203.33±35.63 cells were imaged per region and staining. Pictures were made at 40X magnification using bright-field of the Leica microscope DM6000/CTR6500 and DFC310 FX camera. The acquisition settings were optimized for each protein to avoid any saturation of signal, which could affect intensity calculations 16 . Intensity was measured by outlining individual SNc or VTA neurons and calculating average pixel intensity using ImageJ software (http://rsb.info.nih.gov/ij/). To correct for the background, three background intensity readings were taken per field. These readings were then averaged and substracted from the signal intensity within SNc or VTA neurons in the same area to give an accurate reading of protein staining intensity. The signal intensity for a given protein was normalized to a value of one for the SNc or VTA (reference region), depending on the predicted preferential expression at the RNA level. Signal intensity for each protein was then compared to the reference region (value of one) to assess if the intensity was higher or lower. Investigators performing the intensity measurements and quantification of signal intensity were blinded to the target region (SNc and VTA) and protein staining.
Statistical analysis
For this study, statistical analyses were performed using ¨R¨. For the immunohistochemical analysis Mann-Whitney U test (¨wilcox.test¨ with alternative =¨two.sided¨ in the R function) was used to compare the mean intensity of ATP2A3, CRYM and CALB1 in the SNc and VTA. Individual statistical tests are detailed in the figure legends where significance is marked by P < 0.05. The number of subjects/cells used for each experiment is listed in the figure or figure legends. All results are expressed as mean ± SD.
Data availability
RNA sequencing data generated in this study have been submitted to the Gene Expression Omnibus (GEO) of the National Center for Biotechnology Information under the accession number GSE114918. Human samples re-analyzed from the Nichterwitz study 9 are under accession number GSE76514 and mouse adult single cells 8 can be accessed at GSE76381. Previous human microarray studies used to verify SNc stable gene expression were accessed from the European repository ArrayExpress (E-MEXP-1416) 10 or raw data requested to Dr. Kai C. Sonntag 12 . Fig. 3c ). c, Venndiagram representation showing the overlap between stable genes across mouse and human. d-g, PCAs for the mouse dataset 8 when using: mouse stable genes (d), mouse stable list after exclusion of the three common genes (e), human stable genes (f) or human stable list after exclusion of the three common genes g, The accuracy (Acc.) to distinguish those subpopulations is shown as a percentage value. i-l, Similar analysis as (d-g) but applied to human samples (current study and Nichterwitz et al., 2016) 9 . h, m The three common stable genes are sufficient to distinguish SNc and VTA samples in mouse (h) and human (m).
Figure legends
Fig. 3 Identification and validation of cross-species SNc and VTA dopamine neuron
predictive genes. a, Ranked mean accuracy for individual human stable genes, resolving the mouse dataset (La Manno et al., 2016) 8 , upon random exclusion together with any other two genes. Common stable genes between mouse and human are labelled in blue, while additional genes with predictive value in the mouse are labelled in green. b, c In situ hybridization images of midbrain sections of the adult mouse (P56, Allen Brain Atlas) showing RNA expression pattern for Th (coronal in b, sagittal in c), the common markers Serpine2, Zcch12 and Cdh13 (in blue, b) and human stable genes with predictive value in the mouse (green, c), in addition to the mouse VTA stable marker Calb1 also useful for human (see S Fig. 4a ). d, Immunohistochemistry on sections of human midbrain tissue confirmed differential gene expression at the protein level for the stable markers ATP2A3 (SNc), CRYM (VTA) and the mouse VTA stable gene CALB1. Scale bars: (b,c) 1mm for Th and 200µm for remaining markers (d) 50µm for all 3 pannels. GSG1L  ATP2A3  VAT1  RGS16  ZFHX2  CBLN1  SLIT1   CADM1  ZCCHC12  CRYM  FXYD6  SERPINE2  CDH13  PEG3  KCNIP4  EN2  CACNA2D3 PCSK2  OSBPL3  LOC728392 ARHGAP26 NECAB1  PTCHD1  TIMP2  STC1  GNG4 LY6H PEG10
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